Follicular Lymphoma News

The Future of Treatment in Follicular Lymphoma - OncLive



OncLive
 
The Future of Treatment in Follicular Lymphoma 
OncLive
Anas Younes, MD: Follicular lymphoma is a chronic lymphoid malignancy. It's really unique because although it is not curable, it is treatable. The average lifespan these days is about 18 to 20 years, so any patient would require multiple treatments in ...

 


Combination Therapy's Role in Follicular Lymphoma - OncLive



OncLive
 
Combination Therapy's Role in Follicular Lymphoma 
OncLive
Anas Younes, MD: There are 4 isoforms for PI3 kinase?alpha, beta, gamma, and delta?and there are drugs that you can selectively target 1 or more of these isoforms with. So, idelalisib targets delta, duvelisib targets gamma and delta, and copanlisib ...

 


Dr. Winter Discusses Response in Follicular Lymphoma - OncLive



Dr. Winter Discusses Response in Follicular Lymphoma 
OncLive
Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses response in follicular lymphoma. Follicular lymphoma is a rapidly changing field, says Winter. Although recent evidence has shown that most ...

 


Impact of Copanlisib in Follicular Lymphoma - OncLive



OncLive
 
Impact of Copanlisib in Follicular Lymphoma 
OncLive
Anas Younes, MD: There are multiple PI3 kinase inhibitors that are being tested in clinical trials. The only one that is approved by the FDA right now is idelalisib. But just because they're PI3 kinase inhibitors, that doesn't mean that they have the ...

 


Obinutuzumab for the first-line treatment of follicular lymphoma - Pharmacy Today, American Pharmacists Association, pharmacist.com



medwireNews
 
Obinutuzumab for the first-line treatment of follicular lymphoma 
Pharmacy Today, American Pharmacists Association, pharmacist.com
U.K. researchers compared progression-free survival in patients undergoing two different types of immunochemotherapy for follicular lymphoma. The study included 1,202 treatment-naive participants, one-half of whom were randomized to first-line therapy ...
Obinutuzumab may improve follicular lymphoma outcome medwireNews

all 2 news articles » 


Obinutuzumab Delays Progression in Advanced Follicular Lymphoma - Cancer Network



Obinutuzumab Delays Progression in Advanced Follicular Lymphoma 
Cancer Network
Treatment with obinutuzumab along with chemotherapy resulted in longer progression-free survival than rituximab and chemotherapy in patients with previously untreated advanced-stage follicular lymphoma, according to a large randomized trial.

 


FDA Approvals in Follicular Lymphoma and Prostate Cancer ... - OncLive



OncLive
 
FDA Approvals in Follicular Lymphoma and Prostate Cancer ... 
OncLive
FDA approvals in follicular lymphoma and prostate cancer, a biosimilar approved for several cancers, a new drug application in prostate cancer, results from 2 ...

and more » 


Gazyva Reduces Risk of Disease Progression in Follicular Lymphoma Patients, Clinical Trial Finds - Lymphoma News Today



Lymphoma News Today
 
Gazyva Reduces Risk of Disease Progression in Follicular Lymphoma Patients, Clinical Trial Finds 
Lymphoma News Today
Interim analysis of the GALLIUM (NCT01332968) clinical trial shows that treatment with Gazyva plus chemotherapy improves progression-free survival in patients with advanced, CD20-positive, untreated follicular lymphoma. The GALLIUM trial set out to ...

 


Obinutuzumab Better Than Rituximab in Follicular Lymphoma Patients - Rare Disease Report



Rare Disease Report
 
Obinutuzumab Better Than Rituximab in Follicular Lymphoma Patients 
Rare Disease Report
Data from the GALLIUM Study that obinutuzumab-based immunochemotherapy and maintenance therapy is better for follicular lymphoma than rituximab-based ...
PFS up with obinutuzumab-based Tx in follicular lymphoma Medical Xpress
Newer Drug May Prolong Lymphoma Remission - Gears Of Biz Gears Of Biz

all 4 news articles » 


Copanlisib Induces Nearly 1-Year Median PFS in Heavily Pretreated Indolent Lymphoma - OncLive



OncLive
 
Copanlisib Induces Nearly 1-Year Median PFS in Heavily Pretreated Indolent Lymphoma 
OncLive
?The CHRONOS-1 study shows that copanlisib is a very active PI3 kinase inhibitor and we desperately need new drugs for relapsed and refractory follicular lymphoma,? said Cheson. ?It is active, the responses can be durable, and the drug appears to be ...